An Intrinsic B Cell Defect is Required for the Production of Autoantibodies in the Lpr Model of Murine Systemic Autoimmunity
Overview
General Medicine
Affiliations
Mice homozygous for the gene lpr develop marked lymphadenopathy and a spectrum of autoantibodies closely resembling that of human systemic lupus erythematosus. The unusual T cell phenotype of the expanded lymphocyte population and the T-dependence of several antibodies in this strain have suggested that primary T cell abnormalities underlie the autoimmune syndrome. Using double chimeras, we now show that expression of the lpr gene in B cells is absolutely necessary for autoantibody production. Combinations of anti-Thy 1.2 + C' treated bone marrow from congenic strains of C57BL/6 mice, differing only at the immunoglobulin heavy chain (Igh) and lpr loci, were transferred into lethally irradiated B6/lpr mice. Double chimerism was documented by allotype-specific surface IgD and IgM immunofluorescence assay of peripheral blood and by allotype-specific enzyme-linked immunosorbent assay for total IgM in serum. Despite the presence of both +/+ and lpr B cells, IgM and IgG2a anti-chromatin as well as IgM anti-IgG were entirely the products of lpr B cells. Total serum IgG2a and IgG1 were also dominated by the lpr phenotype but not to the same extent. A similar experiment using B6/lpr-Igha recipients confirmed these findings. Additional experiments in which B6/lpr recipients were infused with ratios of donor bone marrow favoring B6.C20 +/+ over B6/lpr showed that even though +/+ B cells were overrepresented, autoantibodies were only of the lpr allotype. In addition, in the presence of lpr B cells, normal B cells showed little response to an exogenous, T cell-dependent antigen. The data thus indicate that lpr B cells manifest an intrinsic abnormality which is essential for autoantibody production in the lpr model.
T cells, murine chronic graft-versus-host disease and autoimmunity.
Eisenberg R, Via C J Autoimmun. 2012; 39(3):240-7.
PMID: 22704961 PMC: 3578438. DOI: 10.1016/j.jaut.2012.05.017.
Jiang C, Loo W, Greenley E, Tung K, Erickson L J Immunol. 2011; 186(11):6136-47.
PMID: 21536804 PMC: 3181142. DOI: 10.4049/jimmunol.1001931.
Cassani B, Poliani P, Marrella V, Schena F, Sauer A, Ravanini M J Exp Med. 2010; 207(7):1525-40.
PMID: 20547828 PMC: 2901059. DOI: 10.1084/jem.20091928.
A perspective on B-cell-targeting therapy for SLE.
Looney R, Anolik J, Sanz I Mod Rheumatol. 2009; 20(1):1-10.
PMID: 19669389 PMC: 3927150. DOI: 10.1007/s10165-009-0213-x.
Puliaeva I, Puliaev R, Shustov A, Haas M, Via C J Immunol. 2008; 181(9):5912-29.
PMID: 18941180 PMC: 2775525. DOI: 10.4049/jimmunol.181.9.5912.